The use of midodrine in patients with advanced heart failure

Congestive Heart Failure

Volumn 15, Issue 3, 2009, Pages 108-111

  Zakir, Ramzan M ^a   Folefack, Alain ^a   Saric, Muhamed ^a   Berkowitz, Robert L ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MIDODRINE; SPIRONOLACTONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; LENGTH OF STAY; MALE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION; SYSTOLIC DYSFUNCTION;

ADRENERGIC ALPHA-AGONISTS; CARDIOMYOPATHIES; DIASTOLE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; MIDODRINE; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; STROKE VOLUME; SYSTOLE; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, LEFT;

EID: 65649114911     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2008.00042.x     Document Type: Article

References (19)

1. American Heart Association. Heart Disease and Stroke Statistics - 2009 Update. Circulation. 2009;119:e21-e181.
2. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure) developed in collaboration with the International Society for Heart and Lung Transplantation endorsed by the Heart Failure Society of America. J Am Coll Cardiol. 2001;38:2101-2113.
3. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429-1435.
4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302.
5. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991; 325(5):303-310.
6. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
7. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-1355.
8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet. 1999;353(9146):9-13.
9. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme. Lancet. 2003; 362(9386):759-766.
10. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40(8):1414-1421.
11. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-1456.
12. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit. 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61.
13. Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care indicators in US hospitals: Analysis of the ADHERE Registry. Arch Intern Med. 2005;165:1469-1477.
14. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297:61-70.
15. Prakash S, Garg AX, Heidenheim AP, et al. Midodrine appears to be safe and effective for dialysis-induced hypotension: A systematic review. Nephrol Dial Transplant. 2004;19(10):2553-2558.
16. Sharma S, Bhambi B. Successful treatment of hypotension associated with stunned myocardium with oral midodrine therapy. J Cardiovasc Pharmacol Ther. 2005;10(1):77-79.
17. Massie B, Armstrong P, Cleland J, et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: Results from the ATLAS trial. Arch Intern Med. 2001;161:165-171.
18. Butler J, Khadim G, Belue R, et al. Tolerability to β-blocker therapy among heart failure patients in clinical practice. J Card Fail. 2003;9:203-209.
19. Kahn KL, Rogers WH, Rubenstein LV. Measuring quality of care explicit process criteria before and after implementation of the DRG-based prospective payment system. JAMA. 1990;264(15):1969